Hypersensitivity and idiosyncratic reactions to oxaliplatin

Cancer

Volumn 97, Issue 9, 2003, Pages 2301-2307

  Thomas, Rebecca R ^a   Quinn, Mary G ^a   Schuler, Barbara ^a   Grem, Jean L ^a  

^a NATIONAL NAVAL MEDICAL CENTER   (United States)

Author keywords

Allergic reactions; Hypersensitivity; Idiosyncratic reactions; Oxaliplatin; Platinum compounds

Indexed keywords

CAPECITABINE; CIMETIDINE; DEXAMETHASONE; DIPHENHYDRAMINE; METHYLPREDNISOLONE SODIUM SUCCINATE; OXALIPLATIN;

ABDOMINAL PAIN; ADULT; ANXIETY DISORDER; ARTICLE; CANCER CHEMOTHERAPY; CASE REPORT; CHILL; COLON CARCINOMA; COLORECTAL CARCINOMA; CONTROLLED STUDY; COUGHING; DRUG HYPERSENSITIVITY; DYSPNEA; ERYTHEMA; FACE EDEMA; FEMALE; FEVER; FLUSHING; HUMAN; HYPOTENSION; IDIOPATHIC DISEASE; MEDLINE; NAUSEA; PRIORITY JOURNAL; PRURITUS; RASH; RESPIRATORY DISTRESS; SIDE EFFECT; TACHYCARDIA; VERTIGO; VISUAL DISORDER; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTIEMETICS; ANTINEOPLASTIC AGENTS; CIMETIDINE; DEXAMETHASONE; DIPHENHYDRAMINE; DRUG HYPERSENSITIVITY; DYSPNEA; ERYTHEMA; FEMALE; FEVER; HISTAMINE H2 ANTAGONISTS; HUMANS; MALE; METHYLPREDNISOLONE HEMISUCCINATE; MIDDLE AGED; NEOPLASMS; ORGANOPLATINUM COMPOUNDS;

EID: 0037403431     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11379     Document Type: Article

References (39)

1. Markman M, Kennedy A, Webster K, et al. Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol. 1999;17:1141-1145.
2. Shlebak AA, Clark PI, Green JA. Hypersensitivity and crossreactivity to cisplatin and analogues. Cancer Chemother Pharmacol. 1995;35:349-351.
3. Polyzos A, Tsavaris N, Kosmas C, et al. Hypersensitivity reactions to carboplatin administration are common but not always severe: a 10-year experience. Oncology. 2001;61:129-133.
4. Menczer J, Barda G, Glezerman M, et al. Hypersensitivity reaction to carboplatin. Results of skin tests. Eur J Gynaecol Oncol. 1999;20:214-216.
5. Machover D, Diaz-Rubio E, de Gramont A, et al. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol. 1996;7:95-98.
6. de Gramont A, Vignoud J, Tournigand C, et al. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer. 1997;33:214-219.
7. Becouarn Y, Ychou M, Ducreux M, et al. Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers. J Clin Oncol. 1998;16:2739-2744.
8. deBraud F, Munzone E, Nole F, et al. Synergistic activity of oxaliplatin and 5-fluorouracil in patients with metastatic colorectal cancer with progressive disease while on or after 5-fluorouracil. Am J Clin Oncol. 1998;21:279-283.
9. Gerard B, Bleiberg H, Van Daele D, et al. Oxaliplatin combined to 5-fluorouracil and folinic acid: an effective therapy in patients with advanced colorectal cancer. Anticancer Drugs. 1998;9:301-305.
10. Brienza S, Bensmaïne MA, Soulié P, et al. Oxaliplatin added to 5-fluorouracil-based (5-FU ± FA) therapy in the treatment of 5-FU-pretreated patients with advanced colorectal carcinoma (ACRC): results from the European compassionate-use program. Ann Oncol. 1999;10:1311-1316.
11. Maindrault-Goebel F, Louvet C, Andre T, et al. Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR. Eur J Cancer. 1999; 35:1338-1342.
12. Andre T, Bensmaine MA, Louvet C, et al. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J Clin Oncol. 1999;17:3560-3568.
13. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18:2938-2947.
14. Janinis J, Papakostas P, Samelis G, Skarlos D, Papagianopoulos P, Fountzilas G. Second-line chemotherapy with weekly oxaliplatin and high-dose 5-fluorouracil with folinic acid in metastatic colorectal carcinoma: a Hellenic Cooperative Oncology Group (HeCOG) phase II feasibility study. Ann Oncol. 2000;11:163-167.
15. Martoni A, Mini E, Pinto C, et al. Oxaliplatin and protracted continuous 5-fluorouracil infusion in patients with pretreated advanced colorectal carcinoma. Ann Oncol. 2001;12:519-524.
16. Chau I, Webb A, Cunningham D, et al. Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer. Br J Cancer. 2001;85:1258-1264.
17. Kouroussis C, Souglakos J, Kakolyris S, et al. Oxaliplatin in combination with infusional 5-fluorouracil and leucovorin every 2 weeks as first-line treatment in patients with advanced colorectal cancer: a phase II study. Oncology. 2001; 61:36-41.
18. Maindrault-Goebel F, de Gramont A, Louvet C, et al. Highdose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7). Eur J Cancer. 2001;37:1000-1005.
19. Rosati G, Rossi A, Tucci A, Pizza C, Manzione L. Phase I study of a weekly schedule of oxaliplatin, high-dose leucovorin, and infusional fluorouracil in pretreated patients with advanced colorectal cancer. Ann Oncol. 2001;12:669-674.
20. Zori Comba A, Blajman C, Richardet E, et al. A randomised phase II study of oxaliplatin alone versus oxaliplatin combined with 5-fluorouracil and folinic acid (Mayo Clinic regimen) in previously untreated metastatic colorectal cancer patients. Eur J Cancer. 2001;37:1006-1013.
21. Souglakos J, Mavroudis D, Kakolyris S, et al. Triplet combination with irinotecan plus oxaliplatin plus continuousinfusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter phase II trial. J Clin Oncol. 2002;20:2651-2657.
22. Ravaioli A, Marangolo M, Pasquini E, et al. Bolus fluorouracil and leucovorin with oxaliplatin as first-line treatment in metastatic colorectal cancer. J Clin Oncol. 2002;20:2545-2550.
23. Cheeseman SL, Joel SP, Chester JD, et al. A 'modified de Gramont' regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer. Br J Cancer. 2002;87:393-399.
24. Comella P, Casaretti R, Crucitta E, et al. Oxaliplatin plus raltitrexed and leucovorin-modulated 5-fluorouracil i.v. bolus: a salvage regimen for colorectal cancer patients. Br J Cancer. 2002;86:1871-1875.
25. Tournigand C, Maindrault-Goebel F, Louvet C, et al. Severe anaphylactic reactions to oxaliplatin. Eur J Cancer. 1998;34:1297-1298.
26. Medioni J, Coulon MA, Morere JF, et al. Anaphylaxis after oxaliplatin [letter]. Ann Oncol. 1999;10:610.
27. Larzilliere I, Brandissou S, Breton P, et al. Anaphylactic reaction to oxaliplatin: a case report. Am J Gastroenterol. 1999;94:3387-3388.
28. Alliot C, Messouak D, Beets C, et al. Severe anaphylactic reaction to oxaliplatin [letter]. Clin Oncol. 2001;13:236.
29. Schull B, Kornek GV, Scheithauer W. Idiosyncratic reaction after oxaliplatin: circumvention by use of a continuous infusional administration schedule [letter]. Ann Oncol. 2001; 12:1653-1654.
30. Stahl M, Koster W, Wilke H. Reaction after oxaliplatin - prevention with corticosteroids? [letter]. Ann Oncol. 2001;12:874.
31. Meyer L, Zuberbier T, Worm M, et al. Hypersensitivity reactions to oxaliplatin: cross-reactivity to carboplatin and the introduction of a desensitization schedule [letter]. J Clin Oncol. 2002;20:1146-1147.
32. Santini D, Tonini G, Salerno A, et al. Idiosyncratic reaction after oxaliplatin infusion [letter]. Ann Oncol. 2001;12:132-133.
33. Tonini G, Santini D, Vincenzi B, et al. Oxaliplatin may induce cytokine-release syndrome in colorectal cancer patients. J Biol Regul Homeost Agents. 2002;16:105-109.
34. Elenbaas J. Oxaliplatin. In: Klasco RK, Gelman CR, editors. DRUGDEX® system. MICROMEDEX healthcare series, volume 115. Greenwood Village, CO (Edition expired March 2003). Available at URL: www.micromedex.com
35. Zanotti KM, Rybicki LA, Kennedy AW, et al. Carboplatin skin testing: a skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy. J Clin Oncol. 2001;19:3126-3129.
36. Shukunami K, Kurokawa T, Kubo M, Kaneshima M, Kamitani N, Kotsuji F. Hypersensitivity reaction to carboplatin during treatment for ovarian cancer: successful resolution by replacement with cisplatin. Tumori. 1999;85:297-298.
37. Gutierrez M, Pautier P, Lhomme C. Replacement of carboplatin by oxaliplatin may be one solution for patients treated for ovarian carcinoma who are hypersensitive to carboplatin. J Clin Oncol. 2002;20:353.
38. Broome CB, Schiff RI, Friedman HS. Successful desensitization to carboplatin in patients with systemic hypersensitivity reactions. Med Pediatr Oncol. 1996;26:105-110.
39. Ogle SK, Rose MM, Wildes CT. Development and implementation of a carboplatin desensitization protocol for children with neurofibromatosis, type 1, and hypersensitivity reactions in an outpatient oncology clinic. J Pediatr Oncol Nurs. 2002;19:122-126.